SlideShare una empresa de Scribd logo
1 de 9
Descargar para leer sin conexión
presentation by-
Diksha Kumari
18601911022
B.pharm, 3rd year,6th semester
kininogen
kallidin
bradikinin
Inactive
fragments
/kinins
kallikrein
Amino-peptidase
(+)
Important structural points-
1. Positive amino group in active site
2. Zinc(2+) ion, 2 amino acids away from cationic center.
3. Hydrophobic centers for stabilizing the incoming
substrate
4. Protruding hydrogen’s to stabilize the carbonyl bond of
peptide bond next to the labile peptide.
Drug classification(based on groups which
interact with zinc ion of ACE-
1. Sulfhydryl group
containing drugs
Eg. Captopril
2. Dicarboxylate group
containing drugs
Eg. Enalapril, lisinopril
3. Phosphonate group
containing drugs
Eg. Fosinopril
Structure activity relationship
•The N ring must contain a carboxylic acid to mimic the C-terminal
carboxylate of ACE substrate.
•Large hydrophobic heterocyclic rings(i.e., the N-ring) increases potency
and after pharmacokinetic factors.
•The zinc binding groups can be either sulfhydryl(A), a carboxylic acid(B),
or a phosphinic acid(C).
•X is usually methyl to mimic the side chain of alanine within the di-
carboxylate series, when X= n-butyl amine it produces an orally active
drug.
•Optimum activity occurs when stereochemistry of inhibitor is consistent
with L-amino acids stereochemistry present in normal substrate.
captopril enalapril lisinopril fosinopril perindopril ramipril
Chemical
nature
Sulfhydryl Carboxyl Carboxyl Phosphina
te
Carboxyl carboxyl
Activity
status
Active Prodrug Active Prodrug Prodrug Prodrug
Bio-
availability(
as active
form)
70% 50% 25% 30% 20% 60%
Time to
peak action
1hr 4-6hr 6-8hr 3-5hr 6hr 3-6hr
Elimination 2hr 11hr 12hr 12hr 25-30hr 8-48hr
Mode of
excretion
Renal Renal Renal Renal/
hepatic
Renal Renal
Duration of
action
6-12hr 24hr >=24hr 24hr >24hr >24hr
Daily
dose(mg)
25-150 2.5-40 5-40 10-40 2-8 1.25-10
1-Treatment of hypertension.
2-Treatment of heart failure.
3-Secondry prevention after myocardial infarction.
4-Diabetic nephropathy in insulin-dependent diabetes
mellitus.
Clinical use-
Adverse effects-
•Hypotension
•Hyperkalamia
•Cough
•Rashes
•Angio-edema
•Foetopathic
•Headache
•Dizziness
•Acute renal failure
Drug
interactions-
• Antacids decrease the bio-availability of ACE inhibitors
•With diuretics they cause potential excessive deduction
in blood pressure
•With NSAIDs they show decreased hypotensive effects
•With potassium sparing diuretics they cause
hyperkalamia
•On administration with iron salts there are reduction in
efficacy of the drugs
•With allupurinol there is increased risk of
hypersensitivity.
Reference-
1) Tripathi K.D,Essentials of medical pharmacology. Sixth edition.480-
87
2)Williams, David A, Lemke, Thomas L. Foyes principles of medicinal
chemistry. 6th edition. 739-52

Más contenido relacionado

La actualidad más candente

Sar of phenothiazine by sirajuddin
Sar of phenothiazine by sirajuddinSar of phenothiazine by sirajuddin
Sar of phenothiazine by sirajuddinsirajuddin56
 
H1and h2 receptors
H1and h2 receptorsH1and h2 receptors
H1and h2 receptorsSanjay Gopi
 
Calcium channel blockers - Medicinal chemistry for B.Pharm.
Calcium channel blockers - Medicinal chemistry for B.Pharm.Calcium channel blockers - Medicinal chemistry for B.Pharm.
Calcium channel blockers - Medicinal chemistry for B.Pharm.Purna Nagasree K
 
Antiarrhythmic drugs
Antiarrhythmic drugsAntiarrhythmic drugs
Antiarrhythmic drugsMahendra Mahi
 
ORAL HYPOGLYCEMIC AGENTS MEDICINAL CHEMISTRY
ORAL HYPOGLYCEMIC AGENTS MEDICINAL CHEMISTRYORAL HYPOGLYCEMIC AGENTS MEDICINAL CHEMISTRY
ORAL HYPOGLYCEMIC AGENTS MEDICINAL CHEMISTRYSaurabh Badole
 
Medicinal chemistry-Anticancer agents
Medicinal chemistry-Anticancer agentsMedicinal chemistry-Anticancer agents
Medicinal chemistry-Anticancer agentsDHARMENDRA BARIA
 
H2 antagonist and ppi
H2 antagonist and ppiH2 antagonist and ppi
H2 antagonist and ppinaseefa
 
Industrial production, estimation and utilization of phytoconstituents
Industrial production, estimation and utilization of phytoconstituentsIndustrial production, estimation and utilization of phytoconstituents
Industrial production, estimation and utilization of phytoconstituentsMahewash Sana Pathan
 
Congestive heart failure (chf) medicinal chemistry
Congestive heart failure (chf) medicinal chemistryCongestive heart failure (chf) medicinal chemistry
Congestive heart failure (chf) medicinal chemistryTushar Morankar
 
Antidiabetic agents-medicinal chemistry
Antidiabetic agents-medicinal chemistryAntidiabetic agents-medicinal chemistry
Antidiabetic agents-medicinal chemistryDr Duggirala Mahendra
 

La actualidad más candente (20)

Sar of phenothiazine by sirajuddin
Sar of phenothiazine by sirajuddinSar of phenothiazine by sirajuddin
Sar of phenothiazine by sirajuddin
 
H1and h2 receptors
H1and h2 receptorsH1and h2 receptors
H1and h2 receptors
 
Medicinal Chemistry of Diuretics
Medicinal Chemistry of DiureticsMedicinal Chemistry of Diuretics
Medicinal Chemistry of Diuretics
 
Calcium channel blockers - Medicinal chemistry for B.Pharm.
Calcium channel blockers - Medicinal chemistry for B.Pharm.Calcium channel blockers - Medicinal chemistry for B.Pharm.
Calcium channel blockers - Medicinal chemistry for B.Pharm.
 
Angiotensin converting Enzyme inhibitors
Angiotensin converting Enzyme inhibitorsAngiotensin converting Enzyme inhibitors
Angiotensin converting Enzyme inhibitors
 
Antiarrhythmic drugs
Antiarrhythmic drugsAntiarrhythmic drugs
Antiarrhythmic drugs
 
ORAL HYPOGLYCEMIC AGENTS MEDICINAL CHEMISTRY
ORAL HYPOGLYCEMIC AGENTS MEDICINAL CHEMISTRYORAL HYPOGLYCEMIC AGENTS MEDICINAL CHEMISTRY
ORAL HYPOGLYCEMIC AGENTS MEDICINAL CHEMISTRY
 
Anti Arrhythmic Drugs
Anti Arrhythmic DrugsAnti Arrhythmic Drugs
Anti Arrhythmic Drugs
 
Antianginal drugs
Antianginal drugsAntianginal drugs
Antianginal drugs
 
Diuretics
DiureticsDiuretics
Diuretics
 
Medicinal chemistry-Anticancer agents
Medicinal chemistry-Anticancer agentsMedicinal chemistry-Anticancer agents
Medicinal chemistry-Anticancer agents
 
Sympathomimmetic agents
Sympathomimmetic agentsSympathomimmetic agents
Sympathomimmetic agents
 
1 st unit h2 antagonist
1 st unit h2 antagonist1 st unit h2 antagonist
1 st unit h2 antagonist
 
Diuretics
DiureticsDiuretics
Diuretics
 
Antigout drugs
Antigout drugsAntigout drugs
Antigout drugs
 
H2 antagonist and ppi
H2 antagonist and ppiH2 antagonist and ppi
H2 antagonist and ppi
 
Industrial production, estimation and utilization of phytoconstituents
Industrial production, estimation and utilization of phytoconstituentsIndustrial production, estimation and utilization of phytoconstituents
Industrial production, estimation and utilization of phytoconstituents
 
Congestive heart failure (chf) medicinal chemistry
Congestive heart failure (chf) medicinal chemistryCongestive heart failure (chf) medicinal chemistry
Congestive heart failure (chf) medicinal chemistry
 
Antidiabetic agents-medicinal chemistry
Antidiabetic agents-medicinal chemistryAntidiabetic agents-medicinal chemistry
Antidiabetic agents-medicinal chemistry
 
Cholinergic agent
Cholinergic agentCholinergic agent
Cholinergic agent
 

Similar a ACE Inhibitors

ALKYLATING-AGENTS-1-NEW.pdf
ALKYLATING-AGENTS-1-NEW.pdfALKYLATING-AGENTS-1-NEW.pdf
ALKYLATING-AGENTS-1-NEW.pdfrazee khwaja
 
Drugs affecting calcium balance
Drugs affecting calcium balance Drugs affecting calcium balance
Drugs affecting calcium balance Naser Tadvi
 
Anup p.( k channel opener)
Anup p.( k channel opener)Anup p.( k channel opener)
Anup p.( k channel opener)DR ANUP PETARE
 
Agents affecting renin angiotensin aldosterone system (RAAS)
Agents affecting renin angiotensin aldosterone system (RAAS) Agents affecting renin angiotensin aldosterone system (RAAS)
Agents affecting renin angiotensin aldosterone system (RAAS) Ravish Yadav
 
Hypocalcemia.pptx
Hypocalcemia.pptxHypocalcemia.pptx
Hypocalcemia.pptxPedsnahan
 
Cholinergic drugs 1 (1)
Cholinergic drugs 1 (1)Cholinergic drugs 1 (1)
Cholinergic drugs 1 (1)Mary Hair
 
Hormonal control of Calcium Metabolism
Hormonal control of Calcium MetabolismHormonal control of Calcium Metabolism
Hormonal control of Calcium MetabolismAnbarasi rajkumar
 
study of natural products as leads for new pharmaceuticals for the various cl...
study of natural products as leads for new pharmaceuticals for the various cl...study of natural products as leads for new pharmaceuticals for the various cl...
study of natural products as leads for new pharmaceuticals for the various cl...Subham Kumar Vishwakarma
 
drugs acting cvs system
drugs acting cvs system drugs acting cvs system
drugs acting cvs system MansiPanwar14
 
Non steroidal anti-inflammatory drugs
Non steroidal  anti-inflammatory drugsNon steroidal  anti-inflammatory drugs
Non steroidal anti-inflammatory drugsMukesh Suhag
 
newmicrosoftofficepowerpointpresentation-160518101853 (1).pdf
newmicrosoftofficepowerpointpresentation-160518101853 (1).pdfnewmicrosoftofficepowerpointpresentation-160518101853 (1).pdf
newmicrosoftofficepowerpointpresentation-160518101853 (1).pdfDRxAshwiniM
 
Hepatoprotective Activity of Chara Parpam in Ccl4 Induced Rats
Hepatoprotective Activity of Chara Parpam in Ccl4 Induced RatsHepatoprotective Activity of Chara Parpam in Ccl4 Induced Rats
Hepatoprotective Activity of Chara Parpam in Ccl4 Induced RatsIOSR Journals
 

Similar a ACE Inhibitors (20)

Quinolones
QuinolonesQuinolones
Quinolones
 
ALKYLATING-AGENTS-1-NEW.pdf
ALKYLATING-AGENTS-1-NEW.pdfALKYLATING-AGENTS-1-NEW.pdf
ALKYLATING-AGENTS-1-NEW.pdf
 
Drugs affecting calcium balance
Drugs affecting calcium balance Drugs affecting calcium balance
Drugs affecting calcium balance
 
Anup p.( k channel opener)
Anup p.( k channel opener)Anup p.( k channel opener)
Anup p.( k channel opener)
 
Agents affecting renin angiotensin aldosterone system (RAAS)
Agents affecting renin angiotensin aldosterone system (RAAS) Agents affecting renin angiotensin aldosterone system (RAAS)
Agents affecting renin angiotensin aldosterone system (RAAS)
 
Hypocalcemia.pptx
Hypocalcemia.pptxHypocalcemia.pptx
Hypocalcemia.pptx
 
Cholinergic drugs 1 (1)
Cholinergic drugs 1 (1)Cholinergic drugs 1 (1)
Cholinergic drugs 1 (1)
 
Drug evaluation for parkinson's disease 04-01-2020
Drug evaluation for parkinson's disease  04-01-2020Drug evaluation for parkinson's disease  04-01-2020
Drug evaluation for parkinson's disease 04-01-2020
 
DRUG METABOLISM
DRUG METABOLISMDRUG METABOLISM
DRUG METABOLISM
 
Hormonal control of Calcium Metabolism
Hormonal control of Calcium MetabolismHormonal control of Calcium Metabolism
Hormonal control of Calcium Metabolism
 
study of natural products as leads for new pharmaceuticals for the various cl...
study of natural products as leads for new pharmaceuticals for the various cl...study of natural products as leads for new pharmaceuticals for the various cl...
study of natural products as leads for new pharmaceuticals for the various cl...
 
drugs acting cvs system
drugs acting cvs system drugs acting cvs system
drugs acting cvs system
 
Salicylate poisoning
Salicylate poisoningSalicylate poisoning
Salicylate poisoning
 
Peptic ulcer
Peptic ulcerPeptic ulcer
Peptic ulcer
 
Non steroidal anti-inflammatory drugs
Non steroidal  anti-inflammatory drugsNon steroidal  anti-inflammatory drugs
Non steroidal anti-inflammatory drugs
 
6-rodenticides.pptx
6-rodenticides.pptx6-rodenticides.pptx
6-rodenticides.pptx
 
newmicrosoftofficepowerpointpresentation-160518101853 (1).pdf
newmicrosoftofficepowerpointpresentation-160518101853 (1).pdfnewmicrosoftofficepowerpointpresentation-160518101853 (1).pdf
newmicrosoftofficepowerpointpresentation-160518101853 (1).pdf
 
Antihypertensive drugs PCI.pdf
Antihypertensive drugs PCI.pdfAntihypertensive drugs PCI.pdf
Antihypertensive drugs PCI.pdf
 
Insulin
InsulinInsulin
Insulin
 
Hepatoprotective Activity of Chara Parpam in Ccl4 Induced Rats
Hepatoprotective Activity of Chara Parpam in Ccl4 Induced RatsHepatoprotective Activity of Chara Parpam in Ccl4 Induced Rats
Hepatoprotective Activity of Chara Parpam in Ccl4 Induced Rats
 

Último

Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
The Importance of Mental Health: Why is Mental Health Important?
The Importance of Mental Health: Why is Mental Health Important?The Importance of Mental Health: Why is Mental Health Important?
The Importance of Mental Health: Why is Mental Health Important?Ryan Addison
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...bkling
 

Último (20)

Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
The Importance of Mental Health: Why is Mental Health Important?
The Importance of Mental Health: Why is Mental Health Important?The Importance of Mental Health: Why is Mental Health Important?
The Importance of Mental Health: Why is Mental Health Important?
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...
 

ACE Inhibitors

  • 3. Important structural points- 1. Positive amino group in active site 2. Zinc(2+) ion, 2 amino acids away from cationic center. 3. Hydrophobic centers for stabilizing the incoming substrate 4. Protruding hydrogen’s to stabilize the carbonyl bond of peptide bond next to the labile peptide.
  • 4. Drug classification(based on groups which interact with zinc ion of ACE- 1. Sulfhydryl group containing drugs Eg. Captopril 2. Dicarboxylate group containing drugs Eg. Enalapril, lisinopril 3. Phosphonate group containing drugs Eg. Fosinopril
  • 5. Structure activity relationship •The N ring must contain a carboxylic acid to mimic the C-terminal carboxylate of ACE substrate. •Large hydrophobic heterocyclic rings(i.e., the N-ring) increases potency and after pharmacokinetic factors. •The zinc binding groups can be either sulfhydryl(A), a carboxylic acid(B), or a phosphinic acid(C). •X is usually methyl to mimic the side chain of alanine within the di- carboxylate series, when X= n-butyl amine it produces an orally active drug. •Optimum activity occurs when stereochemistry of inhibitor is consistent with L-amino acids stereochemistry present in normal substrate.
  • 6. captopril enalapril lisinopril fosinopril perindopril ramipril Chemical nature Sulfhydryl Carboxyl Carboxyl Phosphina te Carboxyl carboxyl Activity status Active Prodrug Active Prodrug Prodrug Prodrug Bio- availability( as active form) 70% 50% 25% 30% 20% 60% Time to peak action 1hr 4-6hr 6-8hr 3-5hr 6hr 3-6hr Elimination 2hr 11hr 12hr 12hr 25-30hr 8-48hr Mode of excretion Renal Renal Renal Renal/ hepatic Renal Renal Duration of action 6-12hr 24hr >=24hr 24hr >24hr >24hr Daily dose(mg) 25-150 2.5-40 5-40 10-40 2-8 1.25-10
  • 7. 1-Treatment of hypertension. 2-Treatment of heart failure. 3-Secondry prevention after myocardial infarction. 4-Diabetic nephropathy in insulin-dependent diabetes mellitus. Clinical use- Adverse effects- •Hypotension •Hyperkalamia •Cough •Rashes •Angio-edema •Foetopathic •Headache •Dizziness •Acute renal failure
  • 8. Drug interactions- • Antacids decrease the bio-availability of ACE inhibitors •With diuretics they cause potential excessive deduction in blood pressure •With NSAIDs they show decreased hypotensive effects •With potassium sparing diuretics they cause hyperkalamia •On administration with iron salts there are reduction in efficacy of the drugs •With allupurinol there is increased risk of hypersensitivity.
  • 9. Reference- 1) Tripathi K.D,Essentials of medical pharmacology. Sixth edition.480- 87 2)Williams, David A, Lemke, Thomas L. Foyes principles of medicinal chemistry. 6th edition. 739-52